Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Tools to Personalize Medical Education - Dr. Phil Xiu, Editor-in-Chief for Elsevier’s ClinicalKey Student Assessment

Tools to Personalize Medical Education - Dr. Phil Xiu, Editor-in-Chief for Elsevier’s ClinicalKey Student Assessment

FromRaise the Line


Tools to Personalize Medical Education - Dr. Phil Xiu, Editor-in-Chief for Elsevier’s ClinicalKey Student Assessment

FromRaise the Line

ratings:
Length:
26 minutes
Released:
Apr 11, 2023
Format:
Podcast episode

Description

One effective approach to teaching is to identify where students may have some weaknesses and then provide them with additional resources or information to shore up their understanding of that topic. Well, that’s exactly what Elsevier’s ClinicalKey Student Assessment is designed to do, and because it’s an online platform, the process is efficient for both instructors and students. “It’s a foundation to help students in that journey of self-discovery and self-learning which, hopefully, will set them up for the rest of their careers,” says Dr. Phil Xiu, the platform’s editor-in-chief. Xiu’s journey to that role includes many years of involvement in medical education and health tech, from writing textbooks to becoming the series editor of Elsevier’s Crash Course book series which has sold over a million copies and been translated into eight different languages. In this enlightening conversation with host Michael Carrese you'll also learn about efforts to improve diversity, equity and inclusion in medical training, how blockchain technology is being used to enhance patient access to their complete medical record, and how being a practicing family physician shapes Xiu’s work as an educator.
Released:
Apr 11, 2023
Format:
Podcast episode

Titles in the series (100)

Osmosis.org explores solutions with top experts to strengthen the capacity of our healthcare system during the COVID-19 pandemic and beyond.